Recruiting
Investigational
A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
Investigational
- Substances:–
Countries:
Slovenia
Slovenia- Participants:18–64 years
Find therapies in clinical trials near you
- recruiting
- 3 961
- countries
- 28
- conditions
- 2 103
3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today
103 trials match your criteria
Recruiting
Registered drug
A Study Comparing Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy
Registered drug
- Disease:Chronic inflammatory demyelinating polyradiculoneuropathy
- Substances:EmpasiprubartHuman Normal Immunoglobulin (Iv)
Countries:Slovenia
Slovenia- Participants:18–64 years · 65+ years
- Substances:Empasiprubart
Recruiting
Sjogren's syndrome
RecruitingInvestigationalNo placebo
A study to evaluate the safety of dazodalibep in patients with Sjögren's Syndrome over a long period of time
InvestigationalNo placebo
- Disease:Sjogren's syndrome
- Substances:Dazodalibep
Countries:Slovenia
Slovenia- Participants:18–64 years · 65+ years
- Substances:Dazodalibep
Recruiting
Study on Baxdrostat and Dapagliflozin for Preventing Heart Failure in Patients at High Risk
RecruitingRegistered drug
Study on Baxdrostat and Dapagliflozin for Preventing Heart Failure in Patients at High Risk
Registered drug
- Substances:BaxdrostatDapagliflozin
Countries:Slovenia
Slovenia- Participants:18–64 years · 65+ years
- Substances:Baxdrostat
Recruiting
Cardiac failure
RecruitingRegistered drug
Study on BI 690517 and Empagliflozin for Patients with Heart Failure and Preserved Ejection Fraction
Registered drug
- Disease:Cardiac failure
- Substances:Bi 690517Empagliflozin
Countries:Slovenia
Slovenia- Participants:18–64 years · 65+ years
- Substances:Bi 690517
Recruiting
Partial seizures
RecruitingInvestigationalNo placebo
Study on the Safety of BHV-7000 for Adults with Hard-to-Treat Focal Onset Epilepsy
InvestigationalNo placebo
- Disease:Partial seizures
- Substances:Bhv-7000
Countries:Slovenia
Slovenia- Participants:18–64 years · 65+ years
- Substances:Bhv-7000
Recruiting
Vascular malformation
RecruitingRegistered drugNo placebo
A study to evaluate the effectiveness of bleomycin sulfate for treating patients with low-flow vascular malformations using electrosclerotherapy.
Registered drugNo placebo
- Disease:Vascular malformation
- Substances:Bleomycin Sulfate Ph. Eur.
Countries:Slovenia
Slovenia- Participants:18–64 years · 65+ years
- Substances:Bleomycin Sulfate Ph. Eur.
Recruiting
Secondary progressive multiple sclerosis
RecruitingInvestigational
A study to evaluate the effectiveness and safety of remibrutinib in patients with secondary progressive multiple sclerosis
Investigational
- Disease:Secondary progressive multiple sclerosis
- Substances:Remibrutinib
Countries:Slovenia
Slovenia- Participants:18–64 years · 65+ years
- Substances:Remibrutinib
Recruiting
Investigational
A study to test if empasiprubart can improve function and is safe for adults with chronic inflammatory demyelinating polyneuropathy
Investigational
- Disease:Chronic inflammatory demyelinating polyradiculoneuropathy
- Substances:Empasiprubart
Countries:Slovenia
Slovenia- Participants:18–64 years · 65+ years
- Substances:Empasiprubart
Recruiting
Registered drug
A Study of SAB-142 to Slow the Progression of Type 1 Diabetes in Adults and Children Recently Diagnosed with the Disease
Registered drug
Countries:Slovenia
Slovenia- Participants:0–17 years · 18–64 years
- Substances:Sodium Chloride
Recruiting
Endometrial cancer metastatic
RecruitingRegistered drugNo placebo
A Study of Puxitatug Samrotecan Compared to Chemotherapy for Patients with Advanced Endometrial Cancer After Previous Platinum and Immunotherapy Treatment
Registered drugNo placebo
- Disease:Endometrial cancer metastatic
- Substances:Azd8205Doxorubicin+1
Countries:Slovenia
Slovenia- Participants:18–64 years · 65+ years
- Substances:Azd8205
Recruiting
Neurodevelopmental disorder
RecruitingInvestigationalNo placebo
A Study of Gene Replacement Therapy for Children with CTNNB1 Syndrome Using Adeno-Associated Viral Vector Serotype 9 Containing the Human CTNNB1 Gene
InvestigationalNo placebo
- Disease:Neurodevelopmental disorder
- Substances:ADENO-ASSOCIATED VIRAL VECTOR SEROTYPE 9 CONTAINING THE HUMAN CTNNB1 GENE
Countries:Slovenia
Slovenia- Participants:0–17 years
- Substances:ADENO-ASSOCIATED VIRAL VECTOR SEROTYPE 9 CONTAINING THE HUMAN CTNNB1 GENE